1. Bortezomib Is Effective in the Treatment of T Lymphoblastic Leukaemia by Inducing DNA Damage, WEE1 Downregulation, and Mitotic Catastrophe
   Rahman Ud Din et al, 2023, International Journal of Molecular Sciences CrossRef
2. Imaging Very Late Antigen-4 on MOLT4 Leukemia Tumors with Cysteine Site-Specific 89Zr-Labeled Natalizumab Immuno-Positron Emission Tomography
   Mina Kim et al, 2024, Molecular Pharmaceutics CrossRef
3. Switching to Bortezomib may Improve Recovery From Severe Vincristine Neuropathy in Pediatric Acute Lymphoblastic Leukemia
   Jaitri Joshi et al, 2019, Journal of Pediatric Hematology/Oncology CrossRef
4. The Complexity of the Tumor Microenvironment and Its Role in Acute Lymphoblastic Leukemia: Implications for Therapies
   Carolina Simioni et al, 2021, Frontiers in Oncology CrossRef
5. Clinical applications of the naturally occurring or synthetic glycosylated low molecular weight drugs
   Jing Fu et al, 2019, Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part B CrossRef
6. Network pharmacology- and molecular docking-based approach for predicting key targets and the potential mechanism of Tripterygium wilfordii Hook F for the treatment of acute lymphoblastic leukaemia
   Xi Li et al, 2022, All Life CrossRef
7. A Bortezomib-Based Protocol Induces a High Rate of Complete Remission with Minor Toxicity in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
   Boaz Nachmias et al, 2018, Acta Haematologica CrossRef